Andembry
(Garadacimab)ApprovedMonoclonal antibody
CSL BehringThis medication is a monoclonal antibody used to prevent attacks of hereditary angioedema, a genetic condition that causes recurring episodes of painful swelling in various parts of the body including the face, limbs, airway, and digestive tract. It works by blocking certain substances in the body that trigger angioedema symptoms.[2] Andembry is currently approved and in use across 1 indication[4].[1]
Andembry is one of 13 small molecule programs targeting Hereditary Angioedema. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
13 competitors in Hereditary Angioedema
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Neoral
NovartisApproved
Lanoxin
AAdvanz Pharma
Approved
Dawnzera (autoinjector)
Ionis PharmaceuticalsPhase 3
Andembry
CSL BehringApproved
Orladeyo
BBioCryst Pharmaceuticals
Phase 3
Deucrictibant
PPharvaris Netherlands B.V.
Phase 3
KVD900
KKalVista Pharmaceuticals, Ltd.
Phase 3
ADX-324
AADARx Pharmaceuticals, Inc.
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[5]
Jun 16, 2025
ANDEMBRY
BLA BLA761367
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Andembry drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Garadacimab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company